These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 34927013)

  • 41. The LSD1 inhibitor iadademstat (ORY-1001) targets SOX2-driven breast cancer stem cells: a potential epigenetic therapy in luminal-B and HER2-positive breast cancer subtypes.
    Cuyàs E; Gumuzio J; Verdura S; Brunet J; Bosch-Barrera J; Martin-Castillo B; Alarcón T; Encinar JA; Martin ÁG; Menendez JA
    Aging (Albany NY); 2020 Mar; 12(6):4794-4814. PubMed ID: 32191225
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Histone lysine-specific demethylase 1 (LSD1) protein is involved in Sal-like protein 4 (SALL4)-mediated transcriptional repression in hematopoietic stem cells.
    Liu L; Souto J; Liao W; Jiang Y; Li Y; Nishinakamura R; Huang S; Rosengart T; Yang VW; Schuster M; Ma Y; Yang J
    J Biol Chem; 2013 Nov; 288(48):34719-28. PubMed ID: 24163373
    [TBL] [Abstract][Full Text] [Related]  

  • 43. 3,5-Diamino-1,2,4-triazoles as a novel scaffold for potent, reversible LSD1 (KDM1A) inhibitors.
    Kutz CJ; Holshouser SL; Marrow EA; Woster PM
    Medchemcomm; 2014 Dec; 5(12):1863-1870. PubMed ID: 25580204
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Advances toward LSD1 inhibitors for cancer therapy.
    Fu X; Zhang P; Yu B
    Future Med Chem; 2017 Jul; 9(11):1227-1242. PubMed ID: 28722477
    [TBL] [Abstract][Full Text] [Related]  

  • 45. LSD1 inhibitors for anticancer therapy: a patent review (2017-present).
    Lv YX; Tian S; Zhang ZD; Feng T; Li HQ
    Expert Opin Ther Pat; 2022 Sep; 32(9):1027-1042. PubMed ID: 35914778
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Reversible Lysine Specific Demethylase 1 (LSD1) Inhibitors: A Promising Wrench to Impair LSD1.
    Dai XJ; Liu Y; Xue LP; Xiong XP; Zhou Y; Zheng YC; Liu HM
    J Med Chem; 2021 Mar; 64(5):2466-2488. PubMed ID: 33619958
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Crosstalk between lysine-specific demethylase 1 (LSD1) and histone deacetylases mediates antineoplastic efficacy of HDAC inhibitors in human breast cancer cells.
    Vasilatos SN; Katz TA; Oesterreich S; Wan Y; Davidson NE; Huang Y
    Carcinogenesis; 2013 Jun; 34(6):1196-207. PubMed ID: 23354309
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Structurally designed trans-2-phenylcyclopropylamine derivatives potently inhibit histone demethylase LSD1/KDM1 .
    Mimasu S; Umezawa N; Sato S; Higuchi T; Umehara T; Yokoyama S
    Biochemistry; 2010 Aug; 49(30):6494-503. PubMed ID: 20568732
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A Quinquennial Review of Potent LSD1 Inhibitors Explored for the Treatment of Different Cancers, with Special Focus on SAR Studies.
    Sheikh KA; Iqubal A; Alam MM; Akhter M; Khan MA; Ehtaishamul Haque S; Parvez S; Jahangir U; Amir M; Khanna S; Shaquiquzzaman M
    Curr Med Chem; 2024; 31(2):152-207. PubMed ID: 36718063
    [TBL] [Abstract][Full Text] [Related]  

  • 50. An Update of Lysine Specific Demethylase 1 Inhibitor: A Patent Review (2016-2020).
    Zheng YC; Liu YJ; Gao Y; Wang B; Liu HM
    Recent Pat Anticancer Drug Discov; 2022; 17(1):9-25. PubMed ID: 34323202
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prox1 directly interacts with LSD1 and recruits the LSD1/NuRD complex to epigenetically co-repress CYP7A1 transcription.
    Ouyang H; Qin Y; Liu Y; Xie Y; Liu J
    PLoS One; 2013; 8(4):e62192. PubMed ID: 23626788
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pilocarpine-induced seizures associate with modifications of LSD1/CoREST/HDAC1/2 epigenetic complex and repressive chromatin in mice hippocampus.
    Noches V; Rivera C; González MP; Merello G; Olivares-Costa M; Andrés ME
    Biochem Biophys Rep; 2021 Mar; 25():100889. PubMed ID: 33426312
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Lysine-Specific Demethylase 1A as a Promising Target in Acute Myeloid Leukemia.
    Magliulo D; Bernardi R; Messina S
    Front Oncol; 2018; 8():255. PubMed ID: 30073149
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Development and crystallographic evaluation of histone H3 peptide with N-terminal serine substitution as a potent inhibitor of lysine-specific demethylase 1.
    Amano Y; Kikuchi M; Sato S; Yokoyama S; Umehara T; Umezawa N; Higuchi T
    Bioorg Med Chem; 2017 May; 25(9):2617-2624. PubMed ID: 28336409
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Antiviral Properties of the LSD1 Inhibitor SP-2509.
    Harancher MR; Packard JE; Cowan SP; DeLuca NA; Dembowski JA
    J Virol; 2020 Sep; 94(19):. PubMed ID: 32699090
    [TBL] [Abstract][Full Text] [Related]  

  • 56. First-in-Human Phase I Study of Iadademstat (ORY-1001): A First-in-Class Lysine-Specific Histone Demethylase 1A Inhibitor, in Relapsed or Refractory Acute Myeloid Leukemia.
    Salamero O; Montesinos P; Willekens C; Pérez-Simón JA; Pigneux A; Récher C; Popat R; Carpio C; Molinero C; Mascaró C; Vila J; Arévalo MI; Maes T; Buesa C; Bosch F; Somervaille TCP
    J Clin Oncol; 2020 Dec; 38(36):4260-4273. PubMed ID: 33052756
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A novel selective LSD1/KDM1A inhibitor epigenetically blocks herpes simplex virus lytic replication and reactivation from latency.
    Liang Y; Quenelle D; Vogel JL; Mascaro C; Ortega A; Kristie TM
    mBio; 2013 Feb; 4(1):e00558-12. PubMed ID: 23386436
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Histone demethylase LSD1 regulates bone mass by controlling WNT7B and BMP2 signaling in osteoblasts.
    Sun J; Ermann J; Niu N; Yan G; Yang Y; Shi Y; Zou W
    Bone Res; 2018; 6():14. PubMed ID: 29707403
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Lysine-specific demethylase-1 (LSD1) is compartmentalized at nuclear chromocenters in early post-mitotic cells of the olfactory sensory neuronal lineage.
    Kilinc S; Savarino A; Coleman JH; Schwob JE; Lane RP
    Mol Cell Neurosci; 2016 Jul; 74():58-70. PubMed ID: 26947098
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Development of the triazole-fused pyrimidine derivatives as highly potent and reversible inhibitors of histone lysine specific demethylase 1 (LSD1/KDM1A).
    Li Z; Ding L; Li Z; Wang Z; Suo F; Shen D; Zhao T; Sun X; Wang J; Liu Y; Ma L; Zhao B; Geng P; Yu B; Zheng Y; Liu H
    Acta Pharm Sin B; 2019 Jul; 9(4):794-808. PubMed ID: 31384539
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.